How this company measures up on the fundamentals that matter
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | SHERMAN JEFFREY W | Director | 5,000 | $25,000 | |
| 2026-02-27 | THOMAS FRANK E | Director | 5,000 | $25,000 | |
| 2026-02-27 | FLYNN JAMES E | Director and Beneficial Owner of more than 10% of a Class of Security | 5,000,000 | $25,000,000 | |
| 2026-02-27 | HAMILTON THOMAS EDWARD | Director | 100,000 | $500,000 | |
| 2026-01-26 | CELANO MICHAEL | Chief Financial Officer | 37,604 | — | |
| 2026-01-26 | CLAYTON RUSSELL | Officer | 25,637 | — | |
| 2026-01-26 | SHANKAR GOPI | Officer | 25,637 | — | |
| 2026-01-26 | BEN MAIMON CAROLE S | Chief Executive Officer | 100,100 | — | |
| 2025-07-31 | FLYNN JAMES E | Director and Beneficial Owner of more than 10% of a Class of Security | 9,375,000 | $30,000,000 | |
| 2025-01-22 | CELANO MICHAEL | Chief Financial Officer | 34,185 | — |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15